Clínica Planas’ commitment to research is highlighted in their track record as it has dedicated a significant part of its resources to the creation and development of a research department. This unit works to continually train and develop the surgical team in the introduction of new techniques in plastic surgery and in the implementation of our own lines, especially in the field of developing tissue substitutes for their therapeutic use.
This new therapeutic strategy, under the name of tissue engineering, begins to bear fruit in the form of skin, cartilage or artificial bone, which are already on the market. However, the day when we can generate substitutes for more complex tissue units, needed to repair defects - resulting from trauma, cancer or congenital deformities - or replace defective organs is still very far off.
We can obtain these tissues from corpses, but we find problems with rejection and its difficult to control, despite the new immunosuppressive drugs. In an attempt to advance in this field, the team of researchers from the Planas Clinic devised the method to control rejection, which received an award from the Marató de TV3, in its 2000 edition. The method focuses on obtaining endothelial cells through a minimally harmful procedure for the patient. These cells are then modified so that they can regulate the rejection phenomena, and, finally, they are implanted between the endothelium graft where they can best exert their regulatory properties. The Clínica Planas’ research team and the Renal Transplant Service of Hospital del Mar devised this method to control the rejection phenomenon from autologous cells, that’s to say, generated from the recipient of a possible transplant.
Clínica Planas and the spirit of its founder have always been open minded about continuous surgial innovations. The incorporation into the clinical field of new technologies, such as perceptual computation, laser, immunomodulation or tissue engineering, allowing the application of new solutions to increasingly demanding medical challenges.